MedPath

gabapentin and pregabalin on neuropathy caused by Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Phase 2
Conditions
Chronic inflammatory demyelinating polyneuropathy.
Inflammatory polyneuropathy
Registration Number
IRCT20200217046523N16
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
40
Inclusion Criteria

CIDP-induced neuropathy based on neurologist diagnosis
Age over 18 years
No other underlying disease that causes neuropathy
Satisfaction with participation in this study

Exclusion Criteria

Hypersensitivity to venlafaxine, gabapentin and pregabalin
Dissatisfaction with continuing the study

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Intensity of patients' body pain. Timepoint: Before the intervention and once every three months for a year. Method of measurement: Visual Analogue Scale.;Severity of neuropathic pain. Timepoint: Before the intervention and once every three months for a year. Method of measurement: Short form of McGill Pain Questionnaire (SF-MPQ).
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath